Bristol-Myers Squibb Company (NYSE:BMY) finished Thursday with an addition of $0.11 to close at $72.10, an upside of 0.15 percent. An average of 6,016,520 shares of common stock have been traded in the last five days. There was a fall of -$1.23 in the past week, and it reached a new high 34 times over the past 12 months. The last 20 days have seen an average of 9,008,110 shares traded, while the 50-day average volume stands at 9,220,952.
BMY stock has decreased by -8.77% in the last month. The company shares reached their 1-month lowest point of $71.86 on 12/29/22. With the stock rallying to its 52-week high on 12/01/22, shares of the company touched a low of $60.86 and a high of $81.43 in 52 weeks. It has reached a new high 35 times so far this year and achieved 15.64% or $9.75 in price. In spite of this, the price is down -11.46% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
BMY stock investors should be aware that Bristol-Myers Squibb Company (BMY) stock had its last reported insider trading activity 51 days ago on Nov 09. In this transaction, the insider spent $1,307,312. EVP, Research & Early Dev., VESSEY RUPERT, disposed of 45,910 shares at a price of $78.88 on Nov 07. The insider now owns more than $3,621,381 worth of shares. Prior to that, Board Chair and CEO Caforio Giovanni went on to Sale 25,000 shares at $69.71 each on Sep 20. An amount of $1,742,750 was transacted.
Bristol-Myers Squibb Company (BMY) has a trailing price-to-earnings (P/E) ratio of 23.51. The stock’s beta is 0.42. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.32, the price-to-book (PB) ratio at 4.71, and the price-to-cash flow ratio at 19.08.
The company has a payout ratio of 68.30%. The company’s most recent quarterly dividend payment was $0.57 a share, representing a up of 5.56% from $0.54 last year. Its latest increase dividend $0.03 reported on Thursday December 8 2022.
The quick ratio of Bristol-Myers Squibb Company for the three months ended September 29 was 1.30, and the current ratio was 1.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.13 and a total debt to equity ratio of 1.20 for the quarter ending September 29. Its gross profit as reported stood at $36.45 billion compared to revenue of $46.38 billion.
For the three-month period that ended September 29, Bristol-Myers Squibb Company had $1.29 billion in cash and short-term investments compared to $36.97 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $1.61 billion in the quarter, while revenues of $1.42 billion were grew 3.74%. The analyst consensus anticipated Bristol-Myers Squibb Company’s latest quarter earnings to come in at $1.83 per share, but it turned out to be $1.99, a 8.70% surprise. For the quarter, EBITDA amounted to $4.8 billion. Shareholders own equity worth $2.13 billion.
From a technical analysis perspective, let’s take a brief look at Bristol-Myers Squibb Company (BMY) price momentum. RSI 9-day as of the close on 29 December was 23.27%, suggesting the stock is oversold, with historical volatility in this time frame at 13.51%.
As of today, BMY’s price is $72.68 -1.68% or -$1.23 from its 5-day moving average. BMY is currently trading -10.19% lower than its 20-day SMA and -2.30% lower than its 100-day SMA. However, the stock’s current price level is +0.50% above the SMA50 and +3.37% above the SMA200.
The stochastic %K and %D were 3.07% and 4.57%, respectively, and the average true range (ATR) was 1.27. With the 14-day stochastic at 2.67% and the average true range at 1.34, the RSI (14) stands at 29.31%. The stock has reached -0.66 on the 9-day MACD Oscillator while the 14-day reading was at -2.29.
Credit Suisse launched coverage on Bristol-Myers Squibb Company (NYSE: BMY) in its analyst report released on November 18, 2022. The firm assigned the stock a Neutral rating. The consensus rating for Bristol-Myers Squibb Company (BMY) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell BMY, while 10 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 9 others rate it as a “buy”.
What is BMY’s price target for the next 12 months?
Analysts predict a range of price targets between $60.00 and $92.00, with a median target of $83.00. Taking a look at these predictions, the average price target given by analysts for Bristol-Myers Squibb Company (BMY) stock is $80.70.